Identification of LncRNA CASC7/ miR-26/ASPN/TGF-β/Smad Axis in Endometrial Cancer
Identification of LncRNA CASC7/ miR-26/ASPN/TGF-β/Smad Axis in Endometrial Cancer
Xiajun Zhang1, Jie Yang2, Wenjun Zhou1, Zhenshi Chen2, Weidong Wu3, Shaoru Zhang2 and Lihui Wang2*
lncRNA CASC7 is localized to the nucleoplasm (supported) and cell junctions (approved) at human protein level (A) and cells level (B).
lncRNA CASC7 is the prognostic marker in endometrial cancer.
Expression characteristics of ASPN. ASPN is predicted to secreted at human protein level, and there are 2 isoforms in ASPN (A). Tissue-specific expression of ASPN in endometrium and cell-specific is basophil (B).
Analysis of the relationship between lncRNA CASCA7, miR-26 and ASPN. lncRNA CASC7 acts on mir-26, and miR-26 regulates ASPN (A). ASPN gene expression profile across all tumor samples and paired normal tissues, and the Most Similar Genes (B).
Analysis of gene expression level and correlation. Expression levels of ASPN, TGF-β1, TGF-β2, TGF-β3, SMAD2, SMAD3, SMAD4 and XIAP (A). ASPN was positively correlated with TGF-β1, TGF-β2, TGF-β3, SMAD3 and SMAD4 (B).
Analysis of SNV and Pathway Activity. (A) SNV analysis of ASPN, TGFB1, TGFB2, TGFB3, XIAP. (B) Pathway Activity analysis of lncRNA CASC7, ASPN, TGFB1, TGFB2, TGFB3, XIAP.
Schematic representation of the underlying mechanism of lncRNA CASC7/miR-26/ASPN/TGF-β/Smad axis in endometrial Cancer. Based on literature materials, we speculate that lncRNA CASC7 inhibited miR-26, inhibited ASPN, inhibited TGF-β, and promoted XIAP, to activate SMAD/XIAP pathway, improving the survival rate and invasiveness of endometrial cancer cells.
